drugset / Trial / NCT00276523
PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery
RandomizedParallel-groupTriple-blindTreatment
Summary
RATIONALE: SCH 54031 (PEG-interferon alfa-2b) may interfere with the growth of tumor cells and slow the growth of head and neck cancer. It may also stop the growth of head and neck cancer by blocking blood flow to the tumor. Giving PEG-interferon alfa-2b before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This randomized phase II trial is studying how well different doses of PEG-interferon alfa-2b work in treating patients with stage II, stage III, or stage IV head and neck cancer that can be removed by surgery.
Timeline
- Start
- 2004-02
- Primary completion
- 2006-03
- Completion
- 2006-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 0.5 mg/kg | Subcutaneous |
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 2.5 mg/kg | Subcutaneous |
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 5 mg/kg | Subcutaneous |